The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus

Here, we show that the US Food and Drug Administration-approved oral drug nitazoxanide (NTZ) broadly amplifies the host innate immune response to viruses and inhibits Ebola virus (EBOV) replication. We find that NTZ enhances retinoic-acid-inducible protein I (RIG-I)-like-receptor, mitochondrial anti...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:iScience
Main Authors: Jasenosky, Luke D., Cadena, Cristhian, Mire, Chad E., Borisevich, Viktoriya, Haridas, Viraga, Ranjbar, Shahin, Nambu, Aya, Bavari, Sina, Soloveva, Veronica, Sadukhan, Supriya, Cassell, Gail H., Geisbert, Thomas W., Hur, Sun, Goldfeld, Anne E.
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6831822/
https://ncbi.nlm.nih.gov/pubmed/31402258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.isci.2019.07.003
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares